Mesoblast (NASDAQ:MESO) Shares Gap Down – Should You Sell?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $20.61, but opened at $20.10. Mesoblast shares last traded at $20.35, with a volume of 22,431 shares.

Analyst Ratings Changes

A number of research analysts recently weighed in on MESO shares. Maxim Group raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Tuesday, September 24th. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Finally, Piper Sandler boosted their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Mesoblast currently has an average rating of “Hold” and an average price target of $13.50.

Mesoblast Stock Performance

The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average is $12.36 and its 200 day moving average is $9.10.

Institutional Investors Weigh In On Mesoblast

Several hedge funds and other institutional investors have recently modified their holdings of MESO. Signaturefd LLC increased its stake in Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the period. Perkins Coie Trust Co increased its stake in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after buying an additional 1,500 shares during the period. Rathbones Group PLC purchased a new position in Mesoblast in the 2nd quarter worth about $95,000. XTX Topco Ltd bought a new stake in Mesoblast during the 2nd quarter valued at about $103,000. Finally, GAMMA Investing LLC boosted its position in Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after buying an additional 1,213 shares during the period. 1.43% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.